Medcap AB Acquires Danish Pharma Company XGX Pharma

Stockholm, June 25, 2025 — Medcap AB, a Swedish investment company specializing in the Life Sciences sector, has announced the acquisition of Danish pharmaceutical company XGX Pharma. The transaction is being executed through Medcap’s subsidiary, Unimedic Pharma. This strategic move is aimed at strengthening Medcap’s position in the Specialty Pharma business area.

The initial purchase price for XGX Pharma is set at 135 million Danish kronor, approximately 200 million Swedish kronor, with payment made in cash. Additionally, the agreement includes a contingent earn-out of up to 140 million Danish kronor, dependent on the gross profit growth of XGX Pharma for the years 2025 and 2026.

Following the announcement, Medcap’s stock experienced a significant surge in early trading on Wednesday, rising by 9.4%. This acquisition is part of Medcap’s ongoing strategy to invest in and develop Swedish research companies that focus on advancing scientific knowledge and technology for improved global health outcomes.

XGX Pharma, which currently employs seven people, is known for its innovative approach in the pharmaceutical industry. The acquisition is expected to enhance Medcap’s portfolio and contribute to its growth in the Life Sciences Tools & Services sector.

As of June 23, 2025, Medcap’s stock was trading at 414 SEK, with a market capitalization of 6.29 billion SEK. The company’s price-to-earnings ratio stands at 30.79, reflecting investor confidence in its growth prospects.

This acquisition aligns with Medcap’s mission to foster advancements in the Life Sciences sector, further solidifying its role as a key player in the Swedish and international markets.